Merck & Co. Inc.'s PD-1 inhibitor Keytruda (pembrolizumab) as a monotherapy is likely to get a more modest slice of the first-line lung cancer pie than some hoped for, following the release of detailed data from the first-line KEYNOTE-042 study on June 3 at the American Society of Clinical Oncology meeting.
The KEYNOTE-042 study tested Keytruda as a monotherapy against combination chemotherapy in 1,274 patients with first-line non-small cell lung cancer (NSCLC), including squamous and non-squamous types, with expression of the PD-L1 biomarker greater than 1% and no EGFR or ALK mutations
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?